You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
明德生物(002932.SZ)業績快報:2021年度淨利潤14.13億元 同比增長201.37%
格隆匯 04-13 20:34

格隆匯4月13日丨明德生物(002932.SZ)發佈2021年度業績快報,實現營業總收入28.30億元,同比增長195.05%;歸屬於母公司所有者的淨利潤14.13億元,同比增長201.37%;歸屬於母公司所有者的扣除非經常性損益的淨利潤14.07億元,同比增長209.10%;基本每股收益14.79元。

2021年國內多地新冠疫情反覆,各地普遍實行新冠核酸檢測的疫情防控政策,增加了對新冠核酸檢測試劑的需求,公司憑藉靈敏度高、操作便捷的產品和優質的客户服務,新冠核酸檢測試劑市佔率持續走高,新冠核酸檢測試劑及服務等相關收入大幅增長。

2021年海外德爾塔和奧密克戎新冠疫情爆發,市場對新冠抗原檢測試劑盒需求增加,公司新冠抗原檢測試劑盒取得歐盟、越南、馬來西亞等多個國家認證,相關收入大幅增加。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account